GINWA ENTERPRISE (GROUP) INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.71 CNY | -1.90% |
|
-5.36% | -9.93% |
| Sales 2021 | 534M 73.76M | Sales 2022 | 579M 80.02M | Capitalization | 2.92B 403M |
|---|---|---|---|---|---|
| Net income 2021 | -18M -2.49M | Net income 2022 | 33M 4.56M | EV / Sales 2021 | 4.74 x |
| Net cash position 2021 | 651M 89.91M | Net cash position 2022 | 564M 77.87M | EV / Sales 2022 | 4.06 x |
| P/E ratio 2021 |
-175
x | P/E ratio 2022 |
87.2
x | Employees | 600 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 60.88% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.90% | ||
| 1 week | -5.36% | ||
| Current month | -4.55% | ||
| 1 month | -7.45% | ||
| 3 months | -7.83% | ||
| 6 months | -8.33% | ||
| Current year | -9.93% |
1 week
6.56
7.14
1 month
6.567.33
Current year
4.538.00
1 year
4.538.10
3 years
4.5310.97
5 years
3.7010.97
10 years
3.7021.75
| Managers | Title | Age | Since |
|---|---|---|---|
Zhuo Jun Han
CEO | Chief Executive Officer | 57 | - |
Ming Sun
DFI | Director of Finance/CFO | 52 | 99-12-31 |
Chuan Qin
BRD | Director/Board Member | 61 | 94-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chuan Qin
BRD | Director/Board Member | 61 | 94-12-31 |
Zhuo Jun Han
CEO | Chief Executive Officer | 57 | - |
Ge Zhao
BRD | Director/Board Member | 51 | 22-03-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 6.71 | -1.90% | 1,969,400 |
| 24-04-17 | 6.84 | +4.11% | 2,302,804 |
| 24-04-16 | 6.57 | -5.47% | 3,361,200 |
| 24-04-15 | 6.95 | -2.39% | 3,711,300 |
| 24-04-12 | 7.12 | +0.42% | 2,601,775 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
Ginwa Enterprise Group Inc is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company operates its businesses through three segments. The Pharmaceutical Industry segment is mainly engaged in the production of pharmaceuticals. The Company's products are divided into four series, including orthopedics, immunology, children's and general medicines, mainly covering chemicals, Chinese patent medicines, active pharmaceutical ingredient and health care products. The Hotel Industry segment is mainly engaged in the operation of hotels. The Pharmaceutical Commercial segment is mainly engaged in the sales of pharmaceuticals. The Company mainly operates its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -9.93% | 346M | |
| +27.97% | 672B | |
| +23.59% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.36% | 211B | |
| -0.64% | 203B | |
| -10.22% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 600080 Stock
